Brexit draft deal: a welcome step but more certainty needed, say lawyers

While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK life sciences bodies submit concerns over ‘no deal’ Brexit

12 November 2018 Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

Big Pharma

Pharma organisations underline Brexit concerns in letter to negotiators

19 July 2017 The Association of the British Pharmaceutical Industry and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Brexit draft deal: a welcome step but more certainty needed, say lawyers

More on this story

Editor's picks

Editor's picks

More features